RCT | Continuous vs. intermittent meropenem administration shows similar mortality and drug-resistance in sepsis patients

Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Do Prolonged Infusions of β-Lactam Antibiotics Improve Outcomes in Critically Ill Patients With Sepsis? – JAMA (free for a limited period)

See also: Visual Abstract

Commentary: Trial finds no difference between continuous, intermittent meropenem for sepsis patients – CIDRAP

Commentary on Twitter

Continuous administration of meropenem, compared with intermittent administration, does not improve clinically relevant outcomes in critically ill patients with #sepsis. https://t.co/eJ9zdGI4k2 #CCR23 pic.twitter.com/8n2eR9qBPe

— JAMA (@JAMA_current) June 16, 2023